Biofeedback
What studies of biofeedback found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 4 findings, all C.
4 outcomes rated · see each below
ME/CFS: D Little or no difference
Based on the strongest evidence, the randomised trial (very low certainty): 2 of 3 findings are D.
3 outcomes rated · see each below
Both together: D Little or no difference
Based on the strongest evidence, compared with another group, not randomised (very low certainty): 4 of 6 findings are D.
6 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: For long COVID, biofeedback might help some people, but research can’t show it yet. For ME/CFS, studies found little or no difference with biofeedback. For long COVID and ME/CFS studied together, studies found little or no difference with biofeedback. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Biofeedback · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Biofeedback · ME/CFS is hereBiofeedback · Both together is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Autonomic symptoms1 study · 13 people took part in biofeedback Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (13 in all); the paper's own effect size: 0.32 (Cohen's d).
Studies with no comparison group15 in the study · 13 with outcome data · 4 weeks · 10 minutes twice daily for a total of 4 weeks, lying down in bed upon waking in the morning and anytime in the evening before sleep
Autonomic symptoms improved.
The evidence is very uncertain about the effect of biofeedback on autonomic symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (13 in all)
- The paper's own effect size: 0.32 (Cohen's d)
See the 1 study
-
- People in the study
- 15 in the study · 13 with outcome data
- Dose
- 10 minutes twice daily for a total of 4 weeks, lying down in bed upon waking in the morning and anytime in the evening before sleep
- Outcome
- COMPASS-31 Composite Autonomic Symptom Score
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 13 people took part in biofeedback Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (13 in all); the paper's own effect size: 0.57 (Cohen's d).
Studies with no comparison group15 in the study · 13 with outcome data · 4 weeks · 10 minutes twice daily for a total of 4 weeks, lying down in bed upon waking in the morning and anytime in the evening before sleep
Daily functioning improved.
The evidence is very uncertain about the effect of biofeedback on daily functioning in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (13 in all)
- The paper's own effect size: 0.57 (Cohen's d)
See the 1 study
-
- People in the study
- 15 in the study · 13 with outcome data
- Dose
- 10 minutes twice daily for a total of 4 weeks, lying down in bed upon waking in the morning and anytime in the evening before sleep
- Outcome
- C19YRS-m functional ability COVID-19 Yorkshire Rehabilitation Scale modified version
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 13 people took part in biofeedback Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (13 in all); the paper's own effect size: 0.66 (Cohen's d).
Studies with no comparison group15 in the study · 13 with outcome data · 4 weeks · 10 minutes twice daily for a total of 4 weeks, lying down in bed upon waking in the morning and anytime in the evening before sleep
Overall symptoms improved.
The evidence is very uncertain about the effect of biofeedback on overall symptoms in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (13 in all)
- The paper's own effect size: 0.66 (Cohen's d)
See the 1 study
-
- People in the study
- 15 in the study · 13 with outcome data
- Dose
- 10 minutes twice daily for a total of 4 weeks, lying down in bed upon waking in the morning and anytime in the evening before sleep
- Outcome
- C19YRS-m global health score COVID-19 Yorkshire Rehabilitation Scale modified version
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Quality of life1 study · 13 people took part in biofeedback Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (13 in all); the paper's own effect size: 0.6 (Cohen's d).
Studies with no comparison group15 in the study · 13 with outcome data · 4 weeks · 10 minutes twice daily for a total of 4 weeks, lying down in bed upon waking in the morning and anytime in the evening before sleep
Quality of life improved.
The evidence is very uncertain about the effect of biofeedback on quality of life in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (13 in all)
- The paper's own effect size: 0.6 (Cohen's d)
See the 1 study
-
- People in the study
- 15 in the study · 13 with outcome data
- Dose
- 10 minutes twice daily for a total of 4 weeks, lying down in bed upon waking in the morning and anytime in the evening before sleep
- Outcome
- EQ5D-5L global health score EuroQol 5 Dimensions
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
ME/CFS
Symptoms
Depression1 study · 13 people took part in biofeedback Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (24 in all); effect size 1.37 (large).
The randomised trial28 randomised · 24 analysed · eight individual training sessions of 50 minutes each at weekly intervals · eight individual training sessions of 50 minutes each at weekly intervals
Depression improved more than in the comparison group.
The evidence is very uncertain about the effect of biofeedback on depression in ME/CFS. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (24 in all)
- Effect size 1.37 (large)
How big was the difference?
1.37, large. The effect size compares biofeedback with get.
See the 1 study
-
- People in the study
- 28 randomised · 24 analysed
- Dose
- eight individual training sessions of 50 minutes each at weekly intervals
- Outcome
- depression between groups Patient Health Questionnaire (PHQ-9)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Fatigue1 study · 13 people took part in biofeedback Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 24 people found no clear difference; a small benefit can't be ruled out.
The randomised trial28 randomised · 24 analysed · eight individual training sessions of 50 minutes each at weekly intervals · eight individual training sessions of 50 minutes each at weekly intervals
No clear difference in fatigue.
The evidence is very uncertain about the effect of biofeedback on fatigue in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 24 people found no clear difference; a small benefit can't be ruled out
Combination: CBT and psychotherapy + Biofeedback159 randomised · 96 started · 92 analysed
Biofeedback and cognitive behavioral therapy for Egyptian adolescents suffering from chronic fatigue syndrome (2015): Fatigue severity (checklist score %), better.
Shown, not counted: biofeedback was given together with other treatments.
See the 1 study
-
- People in the study
- 28 randomised · 24 analysed
- Dose
- eight individual training sessions of 50 minutes each at weekly intervals
- Outcome
- general fatigue Multidimensional Fatigue Inventory (MFI)
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Daily life and health overall
Quality of life1 study · 13 people took part in biofeedback Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 24 people found no clear difference; a small benefit can't be ruled out.
The randomised trial28 randomised · 24 analysed · eight individual training sessions of 50 minutes each at weekly intervals · eight individual training sessions of 50 minutes each at weekly intervals
No clear difference in quality of life.
The evidence is very uncertain about the effect of biofeedback on quality of life in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 24 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 28 randomised · 24 analysed
- Dose
- eight individual training sessions of 50 minutes each at weekly intervals
- Outcome
- physical QoL Short Form General Health Survey (SF36)
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
Both together
Symptoms
Fatigue1 study · 8 (few people) people took part in biofeedback Improvement C
Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (18 in all).
Compared with another group, not randomised18 in the study · 5 weeks · 10 sessions, twice weekly over 5 weeks
Fatigue improved more than in the comparison group.
The evidence is very uncertain about the effect of biofeedback on fatigue in ME/CFS or long COVID. Improvement · very low certainty C
- Serious risk of bias (ROBINS-I)
- Few people (18 in all)
See the 1 study
-
- People in the study
- 18 in the study
- Dose
- 10 sessions, twice weekly over 5 weeks
- Outcome
- severe fatigue between-group test Brief Fatigue Inventory
- Effect
- better
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- Moderate. comparison group: alternate consecutive assignment (quasirandom)
assigned alternately and consecutively to the intervention or control group, in a predefined 1:1 sequence (quasirandom assignment)
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Low. missing data: one experimental dropout due to unrelated health issues; no missing outcome data; no imputation
Only one participant—a 51-year-old woman—discontinued participation in the experimental group due to serious health issues unrelated to the study procedures.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Low. a pre-specified primary outcome in a registered study
Anxiety1 study · 8 (few people) people took part in biofeedback Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (18 in all).
Compared with another group, not randomised18 in the study · 5 weeks · 10 sessions, twice weekly over 5 weeks
No clear difference in anxiety.
The evidence is very uncertain about the effect of biofeedback on anxiety in ME/CFS or long COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- Few people (18 in all)
See the 1 study
-
- People in the study
- 18 in the study
- Dose
- 10 sessions, twice weekly over 5 weeks
- Outcome
- anxiety Zung Self-Rating Anxiety Scale (SAS)
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- Moderate. comparison group: alternate consecutive assignment (quasirandom)
assigned alternately and consecutively to the intervention or control group, in a predefined 1:1 sequence (quasirandom assignment)
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Low. missing data: one experimental dropout due to unrelated health issues; no missing outcome data; no imputation
Only one participant—a 51-year-old woman—discontinued participation in the experimental group due to serious health issues unrelated to the study procedures.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Low. a pre-specified secondary outcome in a registered study
Depression1 study · 8 (few people) people took part in biofeedback Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (18 in all).
Compared with another group, not randomised18 in the study · 5 weeks · 10 sessions, twice weekly over 5 weeks
No clear difference in depression.
The evidence is very uncertain about the effect of biofeedback on depression in ME/CFS or long COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- Few people (18 in all)
See the 1 study
-
- People in the study
- 18 in the study
- Dose
- 10 sessions, twice weekly over 5 weeks
- Outcome
- depression Patient Health Questionnaire (PHQ-9)
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- Moderate. comparison group: alternate consecutive assignment (quasirandom)
assigned alternately and consecutively to the intervention or control group, in a predefined 1:1 sequence (quasirandom assignment)
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Low. missing data: one experimental dropout due to unrelated health issues; no missing outcome data; no imputation
Only one participant—a 51-year-old woman—discontinued participation in the experimental group due to serious health issues unrelated to the study procedures.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Low. a pre-specified secondary outcome in a registered study
Pain1 study · 8 (few people) people took part in biofeedback Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (18 in all).
Compared with another group, not randomised18 in the study · 5 weeks · 10 sessions, twice weekly over 5 weeks
No clear difference in pain.
The evidence is very uncertain about the effect of biofeedback on pain in ME/CFS or long COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- Few people (18 in all)
See the 1 study
-
- People in the study
- 18 in the study
- Dose
- 10 sessions, twice weekly over 5 weeks
- Outcome
- medium to severe pain Pain Visual Analogue Scale (PVAS)
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- Moderate. comparison group: alternate consecutive assignment (quasirandom)
assigned alternately and consecutively to the intervention or control group, in a predefined 1:1 sequence (quasirandom assignment)
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Low. missing data: one experimental dropout due to unrelated health issues; no missing outcome data; no imputation
Only one participant—a 51-year-old woman—discontinued participation in the experimental group due to serious health issues unrelated to the study procedures.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Low. a pre-specified secondary outcome in a registered study
Daily life and health overall
Overall symptoms1 study · 8 (few people) people took part in biofeedback Improvement C
Why this grade: Improvement, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (18 in all); effect size 0.92 (large).
Compared with another group, not randomised18 in the study · 5 weeks · 10 sessions, twice weekly over 5 weeks
Overall symptoms improved more than in the comparison group.
The evidence is very uncertain about the effect of biofeedback on overall symptoms in ME/CFS or long COVID. Improvement · very low certainty C
- Serious risk of bias (ROBINS-I)
- Few people (18 in all)
- Effect size 0.92 (large)
How big was the difference?
0.92, large. The effect size compares biofeedback with treatment-as-usual (tau) control group.
See the 1 study
-
- People in the study
- 18 in the study
- Dose
- 10 sessions, twice weekly over 5 weeks
- Outcome
- aggregated changes across five outcome domains
- Effect
- better
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- Moderate. comparison group: alternate consecutive assignment (quasirandom)
assigned alternately and consecutively to the intervention or control group, in a predefined 1:1 sequence (quasirandom assignment)
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Low. missing data: one experimental dropout due to unrelated health issues; no missing outcome data; no imputation
Only one participant—a 51-year-old woman—discontinued participation in the experimental group due to serious health issues unrelated to the study procedures.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Serious. a either result
Quality of life1 study · 8 (few people) people took part in biofeedback Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people (18 in all).
Compared with another group, not randomised18 in the study · 5 weeks · 10 sessions, twice weekly over 5 weeks
No clear difference in quality of life.
The evidence is very uncertain about the effect of biofeedback on quality of life in ME/CFS or long COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- Few people (18 in all)
See the 1 study
-
- People in the study
- 18 in the study
- Dose
- 10 sessions, twice weekly over 5 weeks
- Outcome
- low quality of life Short-Form Health Survey (SF-12)
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- Moderate. comparison group: alternate consecutive assignment (quasirandom)
assigned alternately and consecutively to the intervention or control group, in a predefined 1:1 sequence (quasirandom assignment)
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Low. missing data: one experimental dropout due to unrelated health issues; no missing outcome data; no imputation
Only one participant—a 51-year-old woman—discontinued participation in the experimental group due to serious health issues unrelated to the study procedures.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Low. a pre-specified secondary outcome in a registered study
Studies of combinations
Outcomes that only studies of biofeedback given together with other treatments looked at. Shown, not graded: they can’t tell what biofeedback did alone.
Daily functioning ME/CFS
Combination: CBT and psychotherapy + Biofeedback159 randomised · 96 started · 92 analysed
Biofeedback and cognitive behavioral therapy for Egyptian adolescents suffering from chronic fatigue syndrome (2015): School attendance (hours/month), better.
Shown, not counted: biofeedback was given together with other treatments.
Pain ME/CFS
Combination: CBT and psychotherapy + Biofeedback159 randomised · 96 started · 92 analysed
Biofeedback and cognitive behavioral therapy for Egyptian adolescents suffering from chronic fatigue syndrome (2015): Headache, better.
Shown, not counted: biofeedback was given together with other treatments.
Side effects
Stopping because of side effects1 study
All four noted a lack of benefit as the major reason for quitting
Heart rate variability biofeedback therapy and graded exercise training in management of chronic fatigue syndrome: An exploratory pilot study. (2017)
All papers
- Heart rate variability biofeedback therapy and graded exercise training in management of chronic fatigue syndrome: An exploratory pilot study.2017 · randomised trial · 28 randomised · 24 analysed
Summary
This exploratory pilot study examined heart rate variability biofeedback therapy (HRV-BF) and graded exercise training (GET) for fatigue, quality of life and depression in women with chronic fatigue syndrome (CFS). Participants were recruited through newspaper advertisements and an Internet web page and treated in an outpatient setting in Germany. A total of 28 women with CFS were randomly assigned; 24 patients were analysed (13 HRV-BF, 11 GET). Both treatments consisted of eight training sessions of 50 minutes at weekly intervals, with a five-month follow-up. General fatigue improved significantly after both HRV-BF and GET. After HRV-BF, fatigue scores improved significantly in all subscales except reduced motivation; after GET, general fatigue improved significantly. There were no significant differences between groups in fatigue. Physical quality of life improved significantly after GET, whereas HRV-BF showed no significant improvement on this subscale. Mental quality of life improved significantly after HRV-BF, but not after GET. Depression reduced significantly after HRV-BF, while GET had no effect on depression. Between groups, there were significant differences in mental quality of life and depression favouring HRV-BF, and no significant difference in physical quality of life. In the GET group, four patients dropped out and terminated therapy prematurely; all four noted a lack of benefit as the reason for quitting. Negative changes included a change in daily routines and role perception, an increase in migraines, a gain in appetite and in weight, stressful conversations, and a depressive episode in GET. Authors state the small sample size as a limitation.
- The Use of Heart Rate Variability-Biofeedback (HRV-BF) as an Adjunctive Intervention in Chronic Fatigue Syndrome (CSF/ME) in Long COVID: Results of a Phase II Controlled Feasibility Trial.2025 · compared with another group · 18 in the study
Summary
This Phase II controlled feasibility trial enrolled 18 participants with Long COVID who met diagnostic criteria for CFS/ME, recruited from the Pain Unit and the Psychiatric Liaison Unit of the University Hospital of Cagliari, Italy. Participants were assigned alternately and consecutively to HRV-BF plus treatment as usual or to treatment as usual alone. HRV-BF consisted of 10 sessions, twice weekly over 5 weeks. Outcomes included dropout, participant satisfaction, side effects on the Simulator Sickness Questionnaire, fatigue (Brief Fatigue Inventory), depression (PHQ-9), anxiety (Zung SAS), health-related quality of life (SF-12), and pain (PVAS). The overall dropout rate was 5.56% (1 out of 18 participants); one participant (11.1%) discontinued in the experimental group due to serious health issues unrelated to the study procedures, and no dropouts occurred in the control group (0%). Satisfaction mean score was 34.37 (SD = 3.2) within a possible range from 8 to 40. SSQ total mean was 24.31 (SD = 35.42), and 12.82 (SD = 15.24) after excluding an outlier. A significantly greater improvement in severe fatigue was observed in the experimental group (H = 4.083, p = 0.043); three people with severe fatigue at the beginning no longer had such a severe level at T1, compared to no improvement in the control group, and two people in the control group worsened versus no worsening in the experimental group. No similar improvement was observed for depression (H = 0.079, p = 0.701), anxiety (H = 0.194, p = 0.658), low quality of life (H = 0.007, p = 0.929), or medium to severe pain (H = 0.175, p = 0.0.894). Aggregated improvements were 27.5% in the experimental group versus 6.67% in the control group (H = 4.136, p = 0.041), and the binomial test was p < 0.0001. The authors state the trial was not powered to evaluate clinical efficacy.
- Using a Wearable Brain Activity Sensing Device in the Treatment of Long COVID Symptoms in an Open-Label Clinical Trial.2025 · no comparison group · 45 in the study
- Longitudinal Progression of Patients with Long COVID Treated in a Post-COVID Clinic: A Cross-Sectional Survey.2024 · no comparison group · 852 in the study · 536 with outcome data
Summary
This cross-sectional follow-up survey asked patients with long COVID seen at a post-COVID clinic (PCoCC) about symptoms and treatments. A total of 852 patients were identified; 536 completed the survey. The mean time from COVID-19 infection to survey completion was 23.2 ± 6.4 months. There was no comparison group; patients rated symptoms at the initial clinic visit (baseline, by recall) and at follow-up on a 1-10 scale, and rated whether treatments were helpful. Surveyed treatments included low-dose naltrexone, vagal nerve stimulator, midodrine, fludrocortisone, pyridostigmine, aripiprazole, plasmapheresis, reishi mushroom and nattokinase/serrapeptase; treatment duration was not reported. Overall functioning median improved from 8 (6, 9) at baseline to 5 (3, 8) at follow-up (P < .001); fatigue improved from 8 (7,10) to 6 (3, 8) and brain fog from 8 (6, 9) to 5 (3, 8) (P < .001 for both). All individual symptoms assessed were significantly improved (P < .001). Only 4.5% (24/536) had recovered completely. Helpful ratings included low-dose naltrexone 45/77 (58%), vagal nerve stimulator 18/34 (53%), plasmapheresis 9/9 (100%), midodrine 7/17 (41%), fludrocortisone 8/17 (47%), pyridostigmine 2/3 (67%), aripiprazole 8/17 (47%), reishi mushroom 8/19 (42%) and nattokinase/serrapeptase 5/9 (56%). A minority worsened in overall function and in fatigue, myalgia and orthostasis; counts, side-effect counts, and withdrawals due to harms were not reported.
- An open trial of biofeedback for long COVID.2024 · no comparison group · 20 in the study · 16 with outcome data
Summary
This single-arm open trial examined whether a six-week biofeedback intervention alleviated symptoms in adults with long COVID. Data were collected from 20 adult participants aged 22–63 who were referred to the study from the UCLA Long COVID Program by their physician; 16 of the 20 participants completed all six sessions of biofeedback and 14 completed an assessment at the three-month post-treatment time point. Participants received six weekly one-hour sessions combining heart rate variability and temperature biofeedback. There was no comparison or control group. Outcomes were self-reported questionnaires covering somatic symptoms, anxiety, depression, sleep, self-efficacy, health anxiety, quality of life and health care use. Participants self-reported significant improvements in somatic, anxiety and depressive symptoms, sleep quality, quality of life and number of “bad days” immediately after the intervention and three months later. Decreased number of medical doctor visits and prescription drug use over the last month, and improved emotional wellbeing, were observed at the three-month time point only. Changes to health anxiety, pain, work absenteeism and self-reported use of OTC drugs were not significant, and the number of hospital admissions and ER visits were not endorsed enough to analyze statistically. Side effects were not reported.
- HEART Rate Variability Biofeedback for LOng COVID Dysautonomia (HEARTLOC): Results of a Feasibility Study.2024 · no comparison group · 15 in the study · 13 with outcome data
Summary
This phase 2 uncontrolled open-label feasibility study enrolled 15 people with Long Covid from the Leeds COVID-19 Rehabilitation Service; 13 datasets were analysed. Participants used heart rate variability biofeedback (HRV-B) with a standardised slow diaphragmatic breathing technique—a 4-second inhale and 6-second exhale through the nose—for 10 minutes twice daily for 4 weeks, using a Polar H10 chest strap and Elite HRV phone application. A Fitbit Charge 5 was worn for a total study period of 6 weeks. There was no control group; pre- and post-intervention measures were compared within participants using Wilcoxon signed rank tests. The C19YRS-m symptom severity score changed from 19.5 to 13.5 (P = 0.001), COMPASS-31 from 38.5 to 32.5 (P = 0.008), WHODAS from 36.3 to 29.4 (P = 0.021), EQ5D-5L global health from 46.3 to 56.7 (P = 0.008), and Fitbit RMSSD from 34.2 to 40.9 (P = 0.048). Fitbit sleep measures showed no statistically significant differences (for example, overall sleep score P = 0.848). Compliance was 92%, with 720 sessions completed. Two participants were excluded from analysis (unrelated health issues; acute respiratory infection), and feedback included that the breathing exercises were difficult for some. The authors state the small sample limits generalisability.
- Biofeedback and cognitive behavioral therapy for Egyptian adolescents suffering from chronic fatigue syndrome2015 · combination: given with other treatments · 159 randomised · 96 started · 92 analysed
Summary
THIS STUDY enrolled 92 Egyptian adolescents with chronic fatigue syndrome (CFS) from schools in Eastern Province, Saudi Arabia, after 298 were screened and 159 found eligible; 63 lost follow-up and four were excluded because they switched groups. Participants were randomly allocated to an interventional group of 50 receiving CBT aided by biofeedback over 18 months in 40–60 sessions ranging from once up to twice weekly and tapered, or a control group of 42 treated conservatively and symptomatically. Outcomes were fatigue severity on the Checklist Individual Strength/Fatigue Assessment Scale, school attendance in hours/month, and self-rated CFS symptoms. At the end of trial, fatigue severity was lower in the interventional group (32.2 ± 3.8 vs 46.5 ± 14.2; difference in means 12.23, 95% CI 7.4–14.8, p=0.02), and school attendance was higher (92.8 ± 18.4 vs 66.6 ± 22.8 hours/month; difference 23.14, 95% CI 20.6–26.8, p=0.004). Within the interventional group, fatigue severity decreased by 23.1 (95% CI 19.2–25.4; p<0.001) and school attendance increased by 34.46 (95% CI 29.8–36.6; p<0.001). Within the control group, changes were not significant: fatigue 4.46 (95% CI 1.12–21.44; p=0.62) and school attendance 3.44 (95% CI 2.12–32.13; p=0.78). Self-rated unrefreshing sleep, headache, and myalgia improved (p=0.002, 0.005, 0.03); joint pains and tender glands did not (p>0.05). Harms were not reported for the interventional group; in the control group, 18 cases showed almost no changes or worsening in outcome parameters.
- Effectiveness and safety of exercise therapy in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a meta-analysis.2025 · systematic review
Summary
This meta-analysis asked whether exercise therapy changes fatigue and harms in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The authors searched PubMed, Web of Science, Embase, and Cochrane to March 2024, with an update on June 7, 2025, and analyzed 13 studies with 1,305 patients: 659 in intervention groups and 646 in control groups. Interventions included aerobic training, guided graded exercise self-help, graded exercise therapy, gradual exercise, and Qigong forms. Control conditions included control, standard medical care, adaptive pacing therapy, CBT, and heart rate variability biofeedback. Outcomes were fatigue scale-14 (FS-14), multidimensional fatigue inventory (MFI-20), and adverse effects. The meta-analysis reported lower total, physical, and mental fatigue scores on FS-14 with exercise therapy than control; on MFI-20, physical fatigue and reduced activity improved, while general fatigue, mental fatigue, and reduced motivation did not differ significantly. Subgroup analysis reported conventional exercise was more favorable for total and physical fatigue, while Qigong was more favorable for mental fatigue. For harms, Clark et al. reported non-serious adverse events in ~1/4 of participants in both the intervention group and the control group, one case of serious adverse events in both groups, and no serious adverse reactions in either group; severe deterioration difference was not evident. Another study reported non-serious adverse events frequently, serious adverse events and severe adverse reactions relatively rare, and severe deterioration uncommon. The authors note publication bias and limitations.
- A mixed-methods systematic review of post-viral fatigue interventions: Are there lessons for long Covid?2021 · systematic review
Summary
This mixed-methods systematic review asked whether post-viral fatigue interventions offer lessons for long Covid. Online databases were searched in October 2020, and 40 papers were selected. The included fatigue interventions involved 25 studies in CFS/ME, nine in fibromyalgia and eight in unexplained fatigue. Treatments varied widely and were compared with controls, typically usual care or waiting lists; fatigue severity was the main outcome. Intervention duration varied and is not quantified in the recorded data. The review reported mean differences for several interventions. The largest mean difference was for the Three Principles/Innate Health programme (MD -39.0, 95% CI -51.8 to -26.2, SMD = 1.670). Group-based CBT also showed reductions (MD -27.5, 95% CI -33.7 to -21.3, SMD = 1.170; MD -23.7, 95% CI -29.2 to -18.2, SMD = 2.266). Smaller mean differences were reported for GET (MD -11.5, 95% CI -17.6 to -5.4, SMD = 0.524) and self-regulation based physical activity (MD -9.9, 95% CI -16.3 to -3.4, SMD = 0.513). TENS (MD -6.0, 95% CI -16.9 to 4.9, SMD = 0.239), Tai Ji Quan (MD -0.4, 95% CI -9.6 to 8.9, SMD = 0.023) and supportive listening (MD 1.06, 95% CI -1.4 to 3.6, SMD = -0.111) showed little or no benefit. Doxycycline mean differences were positive (MD 6.3, 95% CI 3.7 to 8.8, SMD = -0.752; MD 8.75, 95% CI 6.36 to 11.14, SMD = -1.120). No side effects, withdrawals or worsening were reported in the recorded data.
- Is there effective behavioural treatment for children with chronic fatigue syndrome/myalgic encephalomyelitis?2013 · systematic review
Summary
This review asked whether behavioural treatments benefit adolescents with CFS/ME compared with usual care, measured by school attendance and fatigue. It searched Cochrane Library, PubMed, Ovid, Medline and EMBASE and included three RCTs. In Stulemeijer et al (2005), 36 patients in the CBT group were compared with 35 in the control group (usual care and wait list); participants in the CBT arm reported a decrease in the fatigue score of 14.5 (95% CI 7.4 to 21.6) and were attending an additional 18.2% (95% CI 0.8 to 35.5) of school classes compared with controls at 5-month follow-up. In Nijhof et al (2012), 67 patients in the intervention group were compared with 64 in a usual care control group; young people in the CBT arm attended 32.6% more school (95% CI 21.5 to 43.6) and had a fatigue mean difference of −18.3 (95% CI −22.9 to −13.7) at 6 months. In Al-Haggar et al (2006), 50 patients in the CBT group were compared with 46 in the control group; those in the intervention group attended an extra 23.14 (95% CI 20.6 to 26.8) hours of school a month and had fatigue scores lower by 12.23 (95% CI 7.4 to 14.8). The trial reported 159 patients initially but 63 were lost to follow-up. A GET pilot (n=22) reported a modest reduction in fatigue severity in both arms, GET group −0.42 (SD ± 0.31) and resistance training arm −0.12 (SD ± 0.60), but was not powered sufficiently. Side effects were not reported.
- Interventions in pediatric chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review.2013 · systematic review
Summary
This systematic review searched CINAHL, PsycINFO and Medline to May 2012, with a limited update in October 2012, for studies of interventions in children and adolescents with CFS/ME. It included 24 articles based on 21 studies, with variable designs and quality. In Wright (2005), 13 participants were randomized to a structured tailored incremental rehabilitation program or pacing; the review reports improvements in activity and school attendance with the program immediately after treatment compared with pacing. Viner (2004) reported 43% of the treatment group had complete resolution of CFS/ME compared with 4.5% with supportive care. Lim (2002) reported that before an inpatient program 94% attended school less than half-time, and 78% attended full-time or with occasional absences only at follow-up. Szyndler (2003) reported problem improvement or resolution in 31% by clinician rating and 86% by family rating. Van Geelen (2010) reported 52% nearly complete improvement and 48% no improvement. For harms, Rowe (1997) reported adverse effects common, and Nijhof (2012) reported no serious adverse events. The authors state that methodological inadequacies and inconsistent approaches limit interpretation.
- Alternative medical interventions used in the treatment and management of myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia.2010 · systematic review
Summary
The review included 70 controlled clinical trials of alternative and complementary treatments and nonpharmacological supplements for ME/CFS and fibromyalgia; searches ran up to April 2007. It did not have its own treatment arm or comparison group; it summarized trials with control or comparison conditions. The review did not report one treatment dose or duration. Outcomes in included trials covered laboratory tests, physical functioning, psychologic functioning, and quality of life. The review reports that some trials showed at least one positive effect and some showed null or ambiguous results; it states that no firm conclusions can be made. Only three studies (4%) reported adverse side-effects such as bruising and rashes. For acupuncture, three RCTs reported dropout rates of around 15%–35% in all intervention groups. The authors state publication bias: beneficial effects tend to be published while negative results may remain unpublished. They also state the methodological quality of reporting was generally poor and that no definite CAM treatment recommendations can be made for ME/CFS or FM.
- Treatments for Long COVID autonomic dysfunction: a scoping review.2025 · review
Summary
This scoping review included 11 effectiveness studies, 11 guidelines/position statements, and 15 unpublished/ongoing studies of Long COVID autonomic dysfunction. Among comparative data, an NRCS in Italy gave fexofenadine 180 mg/day plus famotidine 40 mg/day to 14 patients and compared them with 13 who received no antihistamines; follow-up increased heart rate was 29% vs. 85% (p = 0.0063) and abdominal disorders 14% vs. 62%. An RCT of 463 patients compared SIM01 with placebo: fatigue alleviation 63% vs. 43% (OR 2.273, 95% CI 1.520–3.397), GI upset 70% vs. 54% (OR 1.995, 95% CI 1.304 to 3.051); quality of life 76.0 vs. 74.5 (p = 0.17) and physical activity p = 0.37 did not differ significantly. Any AE was 9.5% vs. 10.8%. Single-arm studies reported pre-post changes: maraviroc plus pravastatin (18), SSRIs (95; serious side effects 31.6% [30/95], mild 54.7% [52/95]), a nutraceutical (51), multicomponent treatment with salt/water/compression plus bisoprolol (32), HRV biofeedback (13), inspiratory muscle training (26), and SGB (41; vagal response 7.3% [3/41], transient hoarseness 9.8% [4/41]). Review authors state existing studies are often small and uncontrolled.
- Management of chronic fatigue syndrome/myalgic encephalomyelitis in a pediatric population: A scoping review.2020 · review
Summary
This scoping review examined peer-reviewed research on managing chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in a pediatric population aged under 18 years. The authors searched electronic databases and included 29 peer-reviewed research articles; no new participants were enrolled. The review grouped findings under nutrition/dietary components, exercise therapy, psychosocial factors, and multifaceted treatment. Included studies evaluated CBT with biofeedback, the Lightning Process plus standard medical care, aerobic graded exercise versus progressive resistance training, graded activity/exercise with family sessions, dietary changes, pacing versus STAIRway to Health, and other programs. Outcomes included fatigue severity, school attendance, physical function, anxiety and depression, quality of life, and global health. The review reports that included studies found lower fatigue severity and higher school attendance with CBT plus biofeedback, improvement with Lightning Process plus standard medical care, and no significant difference between aerobic graded exercise and progressive resistance training for physical capacity and QOL, while fatigue and depressive symptoms improved only in the aerobic group. No harms, side effects, worsening or withdrawals were reported in the recorded data. The authors state a lack of research in younger children and insufficient evidence for dietary modifications or supplements in prepubescent children.
- Chronic fatigue syndrome and fibromyalgia: clinical assessment and treatment.2001 · review
Summary
This review examined treatment literature for chronic fatigue syndrome (CFS) and fibromyalgia (FM); it did not report its own enrolled participants, setting, or follow-up. It described studies of Ampligen, antidepressants (fluoxetine, amitryptaline), NADH, massage, essential fatty acids, cognitive-behavioral treatment (CBT) and graded activity-oriented CBT (GA/CBT), graded exercise, pacing/envelope theory, and other alternative or interdisciplinary approaches. Duration was reported only for GA/CBT trials: 13 to 16 sessions. Many cited trials had controlled, randomized, or crossover designs, but the review gave no single pooled comparison. In cited studies, fluoxetine had no effect on CFS or depression symptoms in one controlled study and only a temporary effect on depression symptoms in another; a later essential-fatty-acid trial failed to replicate earlier findings; and NSAIDs were not significantly associated with improved outcomes in a meta-analysis of 49 FM treatment studies. About one-third of patients responded favorably to NADH with at least 10% improvement in symptom scores. CFS patient ratings ranked antiallergy/antiyeast diets and biofeedback/stress management at 24–30% favorable to highly favorable. The review notes Ampligen reports of poor outcomes and adverse reactions, states drug hypersensitivity and adverse reactions are not uncommon, and says GA/CBT may trigger symptom flareups in clients without fear-based avoidance. It states that clinical-study participants are usually from tertiary care centers, so representativeness is unclear, and that controversy over theory-driven CBT for CFS remains unresolved. It also states low-level exercise should be discontinued if it worsens symptoms.